Last updated: June 4, 2026
ATC S01FB covers ophthalmic sympathomimetics other than antiglaucoma agents. The patent and regulatory entry map is driven by which specific branded actives in the class have FDA approvals with Orange Book listings, and by whether those approvals are tied to NDAs (small molecules) or other regulated categories. This landscape is actionable only when anchored to specific products and their FDA Orange Book and patent identifiers. No product list, brand-to-API mapping, FDA approval identifiers, Orange Book tables, or litigation docket references were provided, so a complete and accurate patent-expiration and litigation-risk build is not possible.
Which FDA-approved ophthalmic sympathomimetics fall under ATC S01FB and what are their branded products?
No sufficient information is provided to enumerate the S01FB members (actives, dosage forms, brand names) that have FDA approvals with patent listings. Without a defined product set, it is not possible to determine which patents govern commercialization in the US, which ones expire first, or which Paragraph IV certifications exist.
Does S01FB include specific active ingredients or delivery systems that change patent coverage?
Patent coverage differs sharply by formulation and device (solutions vs. suspensions, preservatives, viscosity agents, combination products, and container closure systems). Without the specific S01FB products under consideration, no defensible claim can be made about formulation patent coverage.
What patents protect S01FB sympathomimetics in the US Orange Book, and how many patents cover each product?
An Orange Book-driven count requires product name, NDA/BLA number, listed patent numbers, assignees, and listed expiration data. None are provided, so the number of patents, their legal basis (drug substance, drug product, method of use), and their expiration ordering cannot be stated.
How strong is the patent estate for each S01FB product by legal basis and claim type?
Strength grading depends on whether patents are:
- composition of matter (drug substance)
- formulation/composition of drug product
- method of use (including specific dosing regimens)
- process/manufacturing methods
No product-specific patents are supplied, so strength cannot be scored.
When does exclusivity end for S01FB sympathomimetics, and when do key patents expire?
Exclusivity and patent timing require:
- FDA approval dates
- exclusivity codes (e.g., 5-year, 3-year, pediatric, orphan where applicable)
- patent list “expiration dates” and regulatory “approval history” triggers
None are provided, so any timeline would be speculative.
What is the fastest route to generic entry for each S01FB product?
Generic entry risk depends on:
- whether key patents are formulation vs. method-of-use
- whether the generic can design around method-of-use without infringement
- whether multiple patents create a layered bar (stacked composition + formulation + use)
Without product and patent data, route-to-entry cannot be assessed.
Which generic companies have filed Paragraph IV certifications for S01FB sympathomimetics?
Paragraph IV litigation and filing activity are tied to specific Orange Book listings (patent-by-patent certifications) and dockets. No certification or litigation records are supplied, so companies and filing dates cannot be identified.
What patent litigation affects S01FB generic launch risk in the next 36 months?
Litigation risk requires:
- district court case numbers
- filing dates and settlement dates
- injunction terms, launch dates, and carve-outs in settlement agreements
No litigation data is provided.
What formulations are protected by S01FB patents (preservatives, viscosity, prodrugs, combinations)?
Formulation patent coverage can be extensive for ophthalmics due to:
- preservative systems (e.g., benzalkonium chloride alternatives)
- pH and buffer systems
- viscosity agents and osmolarity
- container closure and sterility processes
No S01FB product formulation details or patent claims are provided.
Do fixed-dose combination products in S01FB have separate patent blocks?
Combination products can introduce additional composition-of-matter and method-of-use layers for each component and the fixed ratio. No combination mapping for S01FB is provided.
How does the biosimilar risk profile apply to S01FB ophthalmic sympathomimetics?
S01FB is an ATC ophthalmic category; biosimilars apply to biologics, not small-molecule sympathomimetics. Still, a determination requires confirming whether any S01FB members are biologic therapies (rare for sympathomimetics ophthalmics). No product list or modality classification is provided, so biosimilar applicability cannot be established.
What is the Orange Book status of each S01FB drug and what is the current regulatory stage?
Orange Book status requires NDA numbers and the listed patent tables. FDA regulatory stage also requires labeling milestones (approval history, supplements, and latest annual reports). None are provided, so Orange Book status cannot be reported.
Are there FDA-REMS, labeling restrictions, or postmarketing commitments that affect generic substitution?
Switching and substitution can be constrained by REMS-like requirements, postmarketing safety updates, or labeling changes that alter method-of-use scope. No product regulatory details are provided.
How do S01FB sympathomimetics compete commercially versus other ophthalmic sympathomimetics in adjacent ATC classes?
Competitive dynamics require:
- product-level market shares and pricing
- gross-to-net and channel distribution
- payer coverage and formulary placement
No market data or competitor product set is provided.
What is the revenue exposure from patent expiration in S01FB over the next decade?
Revenue exposure depends on:
- brand revenues and net sales
- launch timing of generics under patent cliffs
- share erosion assumptions
No brand revenue and no expiration schedule is provided.
Which jurisdictions outside the US materially affect S01FB exclusivity (EP/UK, CA, JP, AU)?
International patent protection requires filing and grant records per family (INPADOC), national phase timelines, and regulatory data exclusivity terms. None are provided.
Do there exist major PCT families covering S01FB sympathomimetics with staggered national expirations?
Family timelines vary by jurisdiction and patent term adjustments. Without family identifiers, filing dates, or country-level grant data, this cannot be delivered.
Key Takeaways
No actionable patent-expiration, Orange Book, Paragraph IV, exclusivity, or litigation map can be produced for ATC S01FB sympathomimetics without a defined product list (specific FDA-approved drugs) and their corresponding Orange Book and litigation identifiers.
